The start-stop scenario surrounding generic competition for Amgen Inc.’s Sensipar (cinacalcet) in the US continues with Piramal Enterprises Ltd. required to halt sales of its generic version of the calcium-sensing receptor agonist, at least for now.
The US District Court for the District of Delaware, acting on Amgen’s emergency motion for an injunction pending appeal, has...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?